Ampliphi Biosciences Corp (OTCMKTS:APHB) was making bigger moves over the last few days, and it has got another reason to continue to do so. The leader in developing antibacterial therapies released a press note informing that the European Patent Office (EPO) has granted it a patent for ‘Bacteriophage-containing Therapeutic Agents’.
Earned patent in Europe
The company stated that the European patent claims will enable the company to move ahead with a number of bacteriophage compositions. These compositions will be used in a variety of combination with antibiotics for the treatment of infection related to biofilm and caused by the bacterium Pseudomonas aeruginosa.In addition, Ampliphi Biosciences Corp (OTCMKTS:APHB) said that the patent will protect its proprietary methods of treatment of infections, which are characterized by biofilms.
Some of the treatment regimens covered following the receipt of patent are treatment of human and animal infections that originated from either a skin burn or skin wound, lung infections like hospital-acquired pneumonia (HAP), urinary tract infection (UTI), cystic fibrosis (CF) or any infection which is caused by a medical device or implant.
Trial may commence next year
At present, Ampliphi Biosciences Corp (OTCMKTS:APHB) is working towards the development of AmpliPhage-001, a bacteriophage mixture that targets P. aeruginosa infections prevalent in patients with CF. The company said that AmpliPhage-001 is expected to undergo clinical trials by next year. The company is likely to collaborate with the Royal Brompton NHS Hospital, situated in London to commence the trials.
Meanwhile, the company’s CEO and Chairman, Jeremy Curnock Cook said that preliminary indications point out that bacteriophage based treatments could restore the effectiveness of antibiotics, which were ineffective earlier. Cook added that if confirmed such treatment regimen will become important to curb the antibiotic resistance issue. With the latest development, the stock of Ampliphi Biosciences Corp (OTCMKTS:APHB) remained unchanged during the last session while the average volume stood at 1.08 million.
